Affordable Access

deepdyve-link
Publisher Website

Presentation, diagnosis, and the role of subcutaneous and sublingual immunotherapy in the management of ocular allergy.

Authors
  • Trivedi, Amruta1, 2
  • Katelaris, Constance1, 2
  • 1 Immunology Department, Campbelltown Hospital, Sydney, Australia. , (Australia)
  • 2 Department of Medicine, Campbelltown Hospital, Sydney, Australia. , (Australia)
Type
Published Article
Journal
Clinical & experimental optometry
Publication Date
Mar 21, 2021
Pages
1–16
Identifiers
DOI: 10.1111/cxo.13129
PMID: 32944983
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Allergic eye disease or ocular allergy is a debilitating condition with a significant impact on quality of life and productivity. As atopy continues to be on the rise, primary care providers are likely to encounter increasing numbers of patients with allergic eye disease. This review outlines the classification and pathophysiology of allergic eye disease and its clinical presentation. This paper does not detail traditional first-line therapies of allergic eye disease but describes the interdisciplinary management between the eye-care provider and allergist. It is recommended that patients with ongoing signs and symptoms of ocular allergy despite first-line therapies be referred for allergen immunotherapy, as it is highly effective for treatment of allergic eye disease. Through induction of immune tolerance, allergen immunotherapy is a disease-modifying therapy that can result in long-term improvement of ocular allergy. A thorough literature review was conducted on the efficacy and safety of allergen immunotherapy, including subcutaneous immunotherapy and sublingual immunotherapy, and its role in allergic eye disease.

Report this publication

Statistics

Seen <100 times